Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Apatinib plus XELOX regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer PatientsWith lymph node metastasis
Chemotherapy Effect|Chemotherapeutic Toxicity|Gastric Cancer
DRUG: Apatinib plus XELOX
Objective response rate (ORR), Both CR and PR according to Response Evaluation Criteria in Solid Tumors RECIST Version 1.1, 3 months
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], The safety of the the perioperative treatment, percentage of grade 3 or 4 adverse events as safety profile of perioperative treatments, 30 days|Pathological response rate (pRR), Briefly, pathCR (Pathological complete rate) was defined as an absence of carcinoma cells in the primary site, and pathologic partial response (pathPR) was defined as less than 10% residual carcinoma cells in the specimen., 30 days|3-year disease free survival rate, 3 years|3-year overall survival rate, 3 years
This is a Single-center, Open-label, Single-arm,Non-randomized exploratory clinical trial evaluating the efficacy and safety of Apatinib plus XELOX regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With lymph node metastasis